Furthermore, BCLAF1 mutations were enriched in older melanoma patients with high TMB: When testing for this association, we found that patients with BCLAF1 mutations had higher log2 (TMB) (9.4) than BCLAF1 WTs (7.6, Welch’s two-tailed t test, p = 2.3 × 10−7) (Fig. 3b), but that there was no significant difference in age between BCLAF1 mutants (62 years) and WTs (60 years, Welch’s two-tailed t test, p = 0.36) (Fig. 3c). This evidence concerns the gene BCLAF1 and melanoma.